{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/rosacea/","result":{"data":{"firstChapter":{"id":"a3d8bb8f-cf98-5320-abe8-71c7b0c3d604","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field d9c5b4a2-091d-425e-b911-727b4c46faf0 --><h1>Rosacea - acne: Summary</h1><!-- end field d9c5b4a2-091d-425e-b911-727b4c46faf0 -->","htmlStringContent":"<!-- begin item 3a76a468-cc1e-4481-b5fe-50208363e8a6 --><!-- begin field af5a17cf-99f9-4c0a-a5db-e6d41991334e --><ul><li>Rosacea (previously known as 'acne rosacea') is a chronic, inflammatory skin condition predominantly affecting the convexities of the centrofacial region (cheeks, chin, nose, and central part of forehead).</li><li>Rosacea should be diagnosed and managed using a 'phenotype approach', based on the presenting features in each person if there is at least one 'diagnostic' or two 'major' clinical features present:<ul><li>Diagnostic features — phymatous changes, persistent erythema.</li><li>Major features — flushing/transient erythema, papules and pustules, telangiectasia, eye symptoms (ocular rosacea).</li><li>Minor features — skin burning and/or stinging sensation, skin dryness, oedema.</li></ul></li><li>Ocular rosacea may be characterized by eye discomfort, irritation, tearing, foreign body sensation, dryness, itching, photophobia, or blurred vision, and present as lid margin telangiectasia, blepharitis or acute lid infection (chalazion or hordeolum), conjunctivitis, keratitis, or anterior uveitis.<ul><li>Eye symptoms or signs may present with or without skin disease.</li></ul></li><li>Rosacea may progress in severity and change to include additional phenotypes, and is often characterized by repeated remissions and exacerbations.</li><li>The exact cause of rosacea remains unclear, and is likely to be multifactorial involving genetic and environmental risk factors, such as:<ul><li>Increasing age.</li><li>Photosensitive skin types.</li><li>Ultraviolet radiation exposure.</li><li>Smoking, alcohol.</li><li>Spicy foods and hot drinks.</li><li>Heat or cold temperature.</li><li>Emotional stress and exercise.</li><li>Colonization with <em>Demodex folliculorum</em> mites.</li></ul></li><li>Assessment of a person with suspected rosacea should include:<ul><li>Asking about symptoms and their onset, distribution, duration, and severity; the frequency and duration of relapses; any psychosocial impact; any trigger factors; previous treatments and symptom response.</li><li>Examining to assess the phenotype, extent, and severity of facial skin involvement, and for features of ocular rosacea.</li></ul></li><li>Management of suspected rosacea should include:<ul><li>Providing advice on sources of information and support.</li><li>Providing advice on self-management measures, including trigger factor avoidance, effective sun protection, and general skincare measures.</li><li>Offering referral to a skin camouflage service, if appropriate.</li><li>Managing any psychosocial co-morbidities. </li><li>Prescribing first-line topical and/or oral drug treatments, depending on the clinical phenotype and severity of disease, and the person's preferences. This may include topical brimonidine for persistent erythema, topical ivermectin for mild-to-moderate papules/pustules, and the addition of oral doxycycline for moderate-to-severe papules/pustules, depending on contraindications.</li><li>Reviewing the person following first-line treatment(s), to assess the clinical response and need for maintenance or alternative therapy.</li></ul></li><li>Referral to a dermatologist should be considered if there is:<ul><li>Persistent erythema or papules/pustules that have not responded to optimal management in primary care.</li><li>Severe telangiectasia that have not responded to self-management advice.</li><li>An uncertain diagnosis.</li></ul></li><li>Referral to a plastic surgeon should be considered if there is:<ul><li>Prominent non-inflamed phymatous disease.</li></ul></li><li>Referral to an ophthalmologist should be arranged, the urgency depending on clinical judgement, if:<ul><li>A serious eye complication, such as keratitis or anterior uveitis, is suspected.</li><li>Other ocular symptoms are severe or have not responded to optimal management in primary care, such as lid hygiene measures and the use of artificial tears/ocular lubricants.</li></ul></li></ul><!-- end field af5a17cf-99f9-4c0a-a5db-e6d41991334e --><!-- end item 3a76a468-cc1e-4481-b5fe-50208363e8a6 -->","topic":{"id":"907deb55-501c-50b0-9c07-5956c70cf201","topicId":"d6855039-5025-454d-b195-d4b0a3763978","topicName":"Rosacea ","slug":"rosacea","aliases":[],"chapters":[{"id":"a3d8bb8f-cf98-5320-abe8-71c7b0c3d604","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"a9c3b514-8e94-52d5-8de7-2caedcdd8ed3","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"efe24f29-88ad-5507-b4b5-ec00c54a404d","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"10634254-4474-5303-9337-e3682fd14514","slug":"changes","fullItemName":"Changes"},{"id":"1ad5ada5-1ed7-5223-b60c-122b20127e1e","slug":"update","fullItemName":"Update"}]},{"id":"832a95da-0571-5031-b437-3cc5568bc7fa","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"59d41997-63c3-57d4-8c29-c4655d090e7a","slug":"goals","fullItemName":"Goals"},{"id":"2c3bc0a5-be4b-5a98-a5d8-02e7cb85b9cb","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f8c34a65-7879-5a21-87df-68739ba5d1f3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9f050a9b-10be-5d79-b662-0099ac611890","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9fcdbb11-1f96-5ae9-aeec-617a9da55e12","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"538579d3-7620-5145-a70f-022ec13226ae","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d0b606da-7836-5c33-8390-23a6dad9e7bd","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"ed198aaf-1444-5590-ab74-c9fdff996b5e","slug":"definition","fullItemName":"Definition"},{"id":"df406671-3834-580f-836a-3c2428245359","slug":"prevalence","fullItemName":"Prevalence"},{"id":"be28c459-5653-506e-937c-5c4d2f7ceecd","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"bc98e144-7d7d-5fa2-97ad-7c1bd8526ca0","slug":"complications","fullItemName":"Complications"},{"id":"1a5cbcf6-2870-5a82-a207-8c8888f907d2","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"d654b61f-b47e-5123-b965-f806f0eb2e6d","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"bd6d5455-d63e-5507-8bdd-028b338047cc","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"30d3265f-84ec-5ac7-a410-bc11cd078ac9","slug":"assessment","fullItemName":"Assessment"},{"id":"e111154d-c82a-5292-b201-f4a12a8a4d17","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"e753e991-54fe-5ab5-96d2-124372f1292f","slug":"management","fullItemName":"Management","subChapters":[{"id":"0e7b3ebf-33f5-5b51-a9ab-81c8dda1332f","slug":"rosacea","fullItemName":"Scenario: Rosacea"}]},{"id":"602c95a0-f64e-593e-85c4-798ea728733b","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"e6e7bc13-b6bd-5b5e-b337-196c3291ee63","slug":"topical-treatments","fullItemName":"Topical treatments"},{"id":"c53198f5-f60b-5fb6-8767-9f9a275329f5","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"}]},{"id":"0db34d3f-c02f-5b8f-8498-90541139bc2a","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"ca47aba9-e0da-5e0a-a1a2-46bfab6fe609","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"5c0a0103-4ed2-586f-8fbd-aaf6fe82f548","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"84966474-462f-592c-b43d-474d1ca89d52","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bb2d8252-c981-52ba-9faf-d9e9450efe7c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f5e586ed-912a-51ab-b246-3a6f6c67e2d1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a60f4af9-1a6a-5a71-9310-2b3fe7d0cb92","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"40a50d91-c85e-5b2c-b283-ca2a9f30c6f0","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"907deb55-501c-50b0-9c07-5956c70cf201","topicId":"d6855039-5025-454d-b195-d4b0a3763978","topicName":"Rosacea ","slug":"rosacea","aliases":[],"topicSummary":"Acne rosacea is a chronic relapsing skin condition affecting the face, characterized by episodes of facial flushing, erythema, telangiectasia.","lastRevised":"Last revised in January 2021","nextPlannedReviewBy":"2025-06-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2025-05","nextPlannedReviewByDisplay":"May 2025","specialities":[{"id":"50071c38-ab10-5ab8-ac70-6bd19a96c24e","name":"Skin and nail","slug":"skin-nail"}],"chapters":[{"id":"a3d8bb8f-cf98-5320-abe8-71c7b0c3d604","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"a9c3b514-8e94-52d5-8de7-2caedcdd8ed3","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"efe24f29-88ad-5507-b4b5-ec00c54a404d","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"10634254-4474-5303-9337-e3682fd14514","slug":"changes","fullItemName":"Changes"},{"id":"1ad5ada5-1ed7-5223-b60c-122b20127e1e","slug":"update","fullItemName":"Update"}]},{"id":"832a95da-0571-5031-b437-3cc5568bc7fa","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"59d41997-63c3-57d4-8c29-c4655d090e7a","slug":"goals","fullItemName":"Goals"},{"id":"2c3bc0a5-be4b-5a98-a5d8-02e7cb85b9cb","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f8c34a65-7879-5a21-87df-68739ba5d1f3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9f050a9b-10be-5d79-b662-0099ac611890","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9fcdbb11-1f96-5ae9-aeec-617a9da55e12","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"538579d3-7620-5145-a70f-022ec13226ae","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d0b606da-7836-5c33-8390-23a6dad9e7bd","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"ed198aaf-1444-5590-ab74-c9fdff996b5e","slug":"definition","fullItemName":"Definition"},{"id":"df406671-3834-580f-836a-3c2428245359","slug":"prevalence","fullItemName":"Prevalence"},{"id":"be28c459-5653-506e-937c-5c4d2f7ceecd","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"bc98e144-7d7d-5fa2-97ad-7c1bd8526ca0","slug":"complications","fullItemName":"Complications"},{"id":"1a5cbcf6-2870-5a82-a207-8c8888f907d2","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"d654b61f-b47e-5123-b965-f806f0eb2e6d","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"bd6d5455-d63e-5507-8bdd-028b338047cc","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"30d3265f-84ec-5ac7-a410-bc11cd078ac9","slug":"assessment","fullItemName":"Assessment"},{"id":"e111154d-c82a-5292-b201-f4a12a8a4d17","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"e753e991-54fe-5ab5-96d2-124372f1292f","slug":"management","fullItemName":"Management","subChapters":[{"id":"0e7b3ebf-33f5-5b51-a9ab-81c8dda1332f","slug":"rosacea","fullItemName":"Scenario: Rosacea"}]},{"id":"602c95a0-f64e-593e-85c4-798ea728733b","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"e6e7bc13-b6bd-5b5e-b337-196c3291ee63","slug":"topical-treatments","fullItemName":"Topical treatments"},{"id":"c53198f5-f60b-5fb6-8767-9f9a275329f5","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"}]},{"id":"0db34d3f-c02f-5b8f-8498-90541139bc2a","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"ca47aba9-e0da-5e0a-a1a2-46bfab6fe609","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"5c0a0103-4ed2-586f-8fbd-aaf6fe82f548","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"84966474-462f-592c-b43d-474d1ca89d52","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bb2d8252-c981-52ba-9faf-d9e9450efe7c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f5e586ed-912a-51ab-b246-3a6f6c67e2d1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a60f4af9-1a6a-5a71-9310-2b3fe7d0cb92","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"40a50d91-c85e-5b2c-b283-ca2a9f30c6f0","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"907deb55-501c-50b0-9c07-5956c70cf201"}},"staticQueryHashes":["3666801979"]}